Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01868594
Recruitment Status : Completed
First Posted : June 4, 2013
Results First Posted : March 4, 2019
Last Update Posted : May 30, 2019
Sponsor:
Information provided by (Responsible Party):
Materia Medica Holding

Tracking Information
First Submitted Date  ICMJE May 27, 2013
First Posted Date  ICMJE June 4, 2013
Results First Submitted Date  ICMJE November 7, 2017
Results First Posted Date  ICMJE March 4, 2019
Last Update Posted Date May 30, 2019
Actual Study Start Date  ICMJE May 7, 2013
Actual Primary Completion Date July 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 1, 2018)
Changes in the Mean Value of HbA1c [ Time Frame: baseline and 12, 24 and 36 weeks of the treatment ]
The HbA1C test was performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) (www.ngsp.org) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay.
Original Primary Outcome Measures  ICMJE
 (submitted: May 30, 2013)
Changes in the Mean Value of HbA1c [ Time Frame: In 12 and 24 weeks of the treatment as compared to the baseline ]
Change History Complete list of historical versions of study NCT01868594 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: November 1, 2018)
  • Change in Fasting Plasma Glucose (Based on the Data of Biochemical Analysis) [ Time Frame: baseline and 4, 12, 24 and 36 weeks of the treatment ]
  • Change in Average Daily Blood Glucose From a 7-point Patient Self-monitoring of Blood Glucose (SMBG) [ Time Frame: baseline and 4, 8, 12, 18, 24, 30 and 36 weeks of the treatment ]
    A 7-point patient self-monitoring of blood glucose (SMBG): three measurements of blood glucose before the meal; three measurements of postprandial blood glucose (1-2 h after the start of the meal) and one measurement at 3:00 a.m.
  • Changes in Lipids (Concentrations of Plasma Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides) [ Time Frame: baseline and 12, 24 and 36 weeks of the treatment ]
    Blood samples (for measurement of fasting plasma glucose, concentrations of plasma total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) are taken under standard conditions: after night break in food taking (at least 12 hours) and prior to administering of insulin morning dose (prandial), prior to any morning medicines intake (including the study drug and permitted concomitant therapy).
  • Changes in Dosage of Insulin (Basal, Prandial and Total Daily Dose Insulin Measured in IU) [ Time Frame: baseline and 36 weeks of the treatment ]
    Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.
  • Changes in Dosage of Total Insulin Measured in IU/kg of Body Weight [ Time Frame: baseline and 36 weeks of the treatment ]
    Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.
  • Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data [ Time Frame: 36 weeks of the treatment ]
    The Diabetes Treatment Satisfaction Questionnaire allows to assess the degree of satisfaction with treatment for diabetes and its complications - retinopathy and nephropathy, how patients' satisfaction and perceived hyper- and hypoglycemia have changed compared to the initial period (before the treatment). The Diabetes Treatment Satisfaction Questionnaire contains six items scored on 7-point scales from +3 (equals "very satisfied") to -3 (equals "very dissatisfied"), with 0 (equals "no change"). These are summed to produce a total Treatment Satisfaction score. Two questions concerning "Perceived Hyperglycaemia" and "Perceived Hypoglycaemia" respectively, are calculated separately. According to these two items, low scores represent good perceived blood glucose control (+3 means "most of the time" of Hyperglycaemia or Hypoglycaemia whereas -3 means "none of the time" of Hyperglycaemia or Hypoglycaemia).
Original Secondary Outcome Measures  ICMJE
 (submitted: May 30, 2013)
  • Fasting plasma glucose (based on the data of biochemical analysis) [ Time Frame: In 4, 12 and 24 weeks of the treatment as compared to the baseline ]
  • Records of the 7-point patient self-monitoring of blood glucose (SMBG) and average daily blood glucose [ Time Frame: During the whole study period (on weeks 4, 8, 12, 18 and 24 of the treatment) as compared to the baseline ]
    Records of the 7-point patient self-monitoring of blood glucose (SMBG): three measurements of blood glucose before the meal; three measurements of postprandial blood glucose (1-2 h after the start of the meal) and one measurement at 3:00 a.m.
  • Mean value of C-peptide [ Time Frame: In 12 and 24 weeks of the treatment as compared to the baseline ]
  • Concentrations of plasma total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides [ Time Frame: In 12 and 24 weeks of the treatment as compared to the baseline ]
    Blood samples (for measurement of fasting plasma glucose, concentrations of plasma C-peptide, total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) are taken under standard conditions: after night break in food taking (at least 8 hours) and prior to administering of insulin morning dose (basal, if patient receives intermediate insulin twice-daily, and prandial), prior to any morning medicines intake (including the study drug and permitted concomitant therapy).
  • Changes in dosage of insulin (basal, prandial and total daily dose insulin measured in IU and IU/kg of body weight) [ Time Frame: In 24 weeks of the treatment as compared to the baseline ]
    Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.
  • Changes in the satisfaction of diabetes treatment [ Time Frame: In 24 weeks of the treatment as compared to the baseline ]
    Based on DTSQ questionnaire data
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus
Official Title  ICMJE Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus
Brief Summary

The purpose of this study is:

  • to assess clinical efficacy of Subetta in the combined treatment of type I diabetes mellitus;
  • to assess safety of Subetta in the combined treatment of type I diabetes mellitus.
Detailed Description

Patients with type I diabetes mellitus are included in the trial. It is concerned those patients, who by the time of the trial receive basal bolus insulin therapy of type I diabetes mellitus, including basal insulin (using long acting medications) and prandial insulin (short and ultra short acting medications), and with poor glycemic control (HbA1c=7.0-10.0%). For patients, which will be included in the trial (mainly middle aged patients without severe complications of diabetes), HbA1c>7.0% is the marker showing that optimal individual goal of glycemic control is not achieved.

HbA1c, fasting plasma glucose, microalbuminuria, estimated glomerular filtration rate, ophthalmoscopy, blood pressure measurement, patient self-monitoring of blood glucose, frequency of hypoglycemia, endocrinologist examination were performed within screening period. Patients without severe diabetes complications are randomized in 2 groups.

If a patient meets inclusion criteria and does not show exclusion criteria he/she is randomized in one of 2 groups: Group 1 - patients receiving standard type I diabetes mellitus therapy + Subetta at a dose of 1 tablet 4 times a day; Group 2 - the group receiving standard type I diabetes mellitus therapy + Placebo under the regimen used for Subetta. The invented names of the drugs containing basal and prandial (meal) insulin should be unchanged for each patient during the whole trial.

All patients will receive glucometers and the appropriate glucose test strips, so they could self monitor blood glucose and register this data in their diaries.

The trial duration is 38 weeks; the main stages of the trial are conducted during screening, then in 4 weeks (Visit 2), in 12 weeks (Visit 3), in 24 weeks (Visit 4) and in 36 weeks (Visit 5). In 1 week after randomization and the onset of the trial therapy and between the visits to the study site (on weeks 8±1, 18±1 and 30±1) an investigator collects data on patient's health and complaints (phone visits) to decide whether it is necessary to arrange unplanned visit to the site.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Condition  ICMJE Type I Diabetes Mellitus
Intervention  ICMJE
  • Drug: Subetta

    Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.

    Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.

    Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).

  • Drug: Placebo

    Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.

    Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).

Study Arms  ICMJE
  • Experimental: Subetta group
    Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included
    Intervention: Drug: Subetta
  • Placebo Comparator: Placebo group
    Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.
    Intervention: Drug: Placebo
Publications * Mkrtumyan A, Romantsova T, Vorobiev S, Volkova A, Vorokhobina N, Tarasov S, Putilovskiy M, Andrianova E, Epstein O. Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Diabetes Res Clin Pract. 2018 Aug;142:1-9. doi: 10.1016/j.diabres.2018.04.044. Epub 2018 May 26.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 14, 2015)
200
Original Estimated Enrollment  ICMJE
 (submitted: May 30, 2013)
150
Actual Study Completion Date  ICMJE July 10, 2016
Actual Primary Completion Date July 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Diagnosed type I diabetes mellitus (according to WHO criteria, 1999 - 2006).
  2. Disease duration no less than 6 months.
  3. Patient's age from 18 to 65 years inclusive.
  4. Level of glycosylated hemoglobin 7.0- 10.0 %.
  5. Glomerular filtration rate ≥ 60 ml/ min/1.73m^2.
  6. Stable dose of basal insulin for the last 3 months. (Permissible fluctuations are ±10%.)
  7. Usage of contraceptive methods by both gender patients of reproductive age during the trial and within 30 days after ending the participation in the trial.
  8. Availability of signed patient information sheet (Informed Consent form) for participation in the clinical trial.

Exclusion Criteria:

  1. Acute diabetes mellitus complications for 3 months prior to inclusion in the trial (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lacticemia, severe hypoglycemia and hypoglycemic coma).
  2. Diabetic retinopathy, preproliferative, proliferative or terminal stages (based on the results of oculist examination during screening period or 6 months prior to the trial).
  3. Diabetic nephropathy, proteinuria stage, chronic kidney disease on 3, 4 or 5 stage.
  4. Diabetic microangiopathy:

    • ishemic heart disease (medical history of a sudden coronary death with successful reanimation, medical history of myocardial infarction, stable exertional angina III or IV FC; unstable angina; post-infarction cardiosclerosis; chronic heart failure III or IV FC);
    • cerebrovascular diseases (medical history of acute cerebrovascular accident; progressive vascular leukoencephalopathy; vascular dementia);
    • chronic obliterative peripheral vascular diseases (clinically significant);
    • diabetic neuroosteoarthropathy;
    • diabetic foot (clinically significant).
  5. Heart rhythm disorder:

    • II-III atrioventricular block;
    • sick sinus syndrome;
    • long QT interval syndrome;
    • complete left bundle branch block;
    • block of 2/3 bundle branches;
    • WPW syndrome;
    • ventricular arrhythmia of III grade according Laun-Wolf;
    • paroxysmal supraventricular tachycardia;
    • paroxysmal/recurrent ventricular tachycardia;
    • atrial flutter and fibrillation;
    • ventricular flutter and fibrillation;
    • heart pacemaker implant.
  6. Uncontrolled arterial hypertension characterized by the following blood tension values: systolic blood pressure over 160 mm Hg and/or diastolic blood pressure over 100 mm Hg.
  7. Severe concomitant pathology including clinically significant cardiovascular diseases of III - IV functional class (according to New York Heart Association classification, 1964), nervous and endocrine system diseases, including morbid obesity (body mass index≥40.0 kg/m2), renal insufficiency, liver failure.
  8. Medical history of pancreatectomy or transplantation of pancreatic/islet cells.
  9. Medical history of renal transplantation.
  10. Malignant neoplasms/suspected malignant neoplasms.
  11. Exacerbations or decompensation of chronic diseases affecting a patient's ability to participate in the clinical trial.
  12. Level of fasting triglycerides >5.64 mmol/L.
  13. Medical history of bariatric surgical operations.
  14. Medical history of polyvalent allergy.
  15. Allergy/ intolerance to any of the components of medications used in the treatment.
  16. Intake of medicines listed in the section "Prohibited concomitant treatment" for 3 months prior to the inclusion in the trial.
  17. Pregnancy, breast-feeding.
  18. Drug addiction, alcohol usage in the amount exceeding 2 units of alcohol per day.
  19. Mental disorders of a patient.
  20. Night work.
  21. Participation in other clinical trials in the course of 3 months prior to the inclusion in the trial.
  22. Patients, who from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the intake regimen of the investigated medicines.
  23. Other factors impeding patient's participation in the trial (for example, planned business trips or journeys).
  24. Patient is related to the research personnel of the investigative site, who are directly involved in the trial or are the immediate relative of the researcher. The immediate relative includes husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.
  25. Patient works for OOO "NPF "Materia Medica Holding" (i.e. is the company's employee, temporary contract worker or appointed official responsible for the carrying out the research) or the immediate relative.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01868594
Other Study ID Numbers  ICMJE MMH-SU-003
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Materia Medica Holding
Study Sponsor  ICMJE Materia Medica Holding
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Materia Medica Holding
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP